通过分子对接和分子动力学模拟探索作为潜在人胰腺脂肪酶抑制剂的橙酮衍生物。
Exploring Aurone Derivatives as Potential Human Pancreatic Lipase Inhibitors through Molecular Docking and Molecular Dynamics Simulations.
机构信息
Faculty of Pharmacy, University of Medicine and Pharmacy at Ho Chi Minh City, Ho Chi Minh City 700000, Vietnam.
出版信息
Molecules. 2020 Oct 13;25(20):4657. doi: 10.3390/molecules25204657.
Inhibition of human pancreatic lipase, a crucial enzyme in dietary fat digestion and absorption, is a potent therapeutic approach for obesity treatment. In this study, human pancreatic lipase inhibitory activity of aurone derivatives was explored by molecular modeling approaches. The target protein was human pancreatic lipase (PDB ID: 1LPB). The 3D structures of 82 published bioactive aurone derivatives were docked successfully into the protein catalytic active site, using AutoDock Vina 1.5.7.rc1. Of them, 62 compounds interacted with the key residues of catalytic trial Ser152-Asp176-His263. The top hit compound (), with a docking score of -10.6 kcal⋅mol, was subsequently submitted to molecular dynamics simulations, using GROMACS 2018.01. Molecular dynamics simulation results showed that formed a stable complex with 1LPB protein via hydrogen bonds with important residues in regulating enzyme activity (Ser152 and Phe77). Compound showed high potency for further studies, such as the synthesis, in vitro and in vivo tests for pancreatic lipase inhibitory activity.
抑制人胰腺脂肪酶是治疗肥胖症的一种有效方法,人胰腺脂肪酶是膳食脂肪消化和吸收过程中的关键酶。本研究采用分子模拟方法研究了奥rone 衍生物对人胰腺脂肪酶的抑制活性。靶蛋白为人胰腺脂肪酶(PDB ID:1LPB)。使用 AutoDock Vina 1.5.7.rc1 将 82 种已发表的生物活性奥rone 衍生物的 3D 结构成功对接至蛋白催化活性部位。其中,有 62 种化合物与关键残基催化三联 Ser152-Asp176-His263 相互作用。对接得分最低的化合物()为-10.6 kcal⋅mol,随后进行了分子动力学模拟。使用 GROMACS 2018.01 进行分子动力学模拟。分子动力学模拟结果表明,化合物通过与调节酶活性的重要残基(Ser152 和 Phe77)形成氢键,与 1LPB 蛋白形成稳定的复合物。化合物具有较高的抑制人胰腺脂肪酶的潜力,可进一步研究,如合成、体外和体内抑制人胰腺脂肪酶活性试验。